Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Blue Sky Uranium Schedules Start of Drill Program for Ivana Uranium-Vanadium Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CERo Therapeutics Holdings Inc
CERO
Healthcare
Biotechnology
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune...
repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CERO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
•••
Jonathon Brown
X
Post by
Jonathon Brown
on May 15, 2025 8:58am
Buzz on the Bullboards: Quarterly reports and company mergers
This week also marks the heart of quarterly earnings season, when companies disclose their financial and operational performance.
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on May 08, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has...
read article.
QMET Announce Initial Results And Targeted Exploration Plan for Project In Nova Scotia
posted May 22, 2025 9:00am by
Q Precious & Battery Metals Corp.
-
|
Richard Penn, CEO of Q Precious & Battery Metals, commented: "These initial results from Colchester underscore the exceptional efficiency of QIMC’s exploration approach. The rapid identification of priority targets positions us strongly for the next exploration phase." ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 30, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 25, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it...
read article.
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2025 3:16pm
CERO....ma's are aligning...VWAP fast approaching
Heads up
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2025 3:06pm
CERO.... mini pop 1 hr before the close
$1.16 ya pays yo money
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2025 2:36pm
CERO....boring
Watching a deal bleed out is no fun Sticking to the gameplan is crucial TBH....if I did own this....I'd probably add sub 90 cents Just sayin
(107)
•••
Iseneschal
X
Comment by
Iseneschal
on Apr 24, 2025 1:45pm
RE:CERO..possible rally here at $1.14..2 1/2 hrs before close
I'd be a buyer if it busts thru VWAP around $1.22....could see it rip to over $1.32 JMHO
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2025 1:42pm
CERO..possible rally here at $1.14..2 1/2 hrs before close
Good luck Me no position
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 19, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AMLSOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 13, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 06, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays
Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 05, 2025 8:15am
New Press Release - CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14
New poster to highlight preclinical data of CER-1236 in ovarian cancerSOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of...
read article.
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 20, 2025 3:51pm
CERO....funny how that works....I sell and it goes up
Good luck to the Bulls Over $2 now...10 mins til close Any Chasers or FOMO's around???
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 20, 2025 3:31pm
CERO.....sold all into this strength
Cheers !
(107)
•••
Iseneschal
X
Post by
Iseneschal
on Feb 14, 2025 1:37pm
CERO....don't give up...bids are stacking up again
~ $1.95
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Developing a sizeable copper resource with a highly prospective exploration asset in Peru
Identifying new compelling targets on extensive and highly prospective land position